<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210829052319N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-03-17</date_registration>
      <primary_sponsor>Karaj University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of efficacy of two methods of epidural analgesia</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the postoperative epidural analgesic efficacy between epidural catheter and surgical hemo-vac drain with epidural injection capability in posterior lumbar surgeries</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-04-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>52</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/59496</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Other, Randomization description: Patients are randomly divided into two groups consisting of quadruple blocks using the non-blinded block randomization method.</study_design>
      <phase>3</phase>
      <hc_freetext>بی دردی اپیدورال بعد از اعمال جراحی لومبار خلفی.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: dexamethasone (4 mg) + ropivacaine (0.2%, 25 ml) + epinephrine (1:200000) using Hemo-vac drain with epidural drug delivery capability. The epidural injection is repeated every 6 hours until 48 hours after the surgery. Intervention 2: Control group: dexamethasone (4 mg) + ropivacaine (0.2%, 25 ml) + epinephrine (1:200000) using an epidural catheter. The epidural injection is repeated every 6 hours until 48 hours after the surgery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Demographic data and measured investigation variables will be accessible.

When:
June. 21 2022 to Sep. 22, 2022

To whom:
Only accredited  investigators or resrarch institutes

Conditions:
Data analysis permission is given to confirm the outcomes of the study and outcomes other than mentioned in this study.

Where to obtain:
Mehdi Rezaee, Anesthesiology Departmant, Madani Hospital, Karaj.Alborz

How to obtain:
Email to : m.rezaei@abzums.ac .ir and request for investigation data، following confirmation of the individual's or institute's identity the data will become accessible through mailing.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehdi Rezaee</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 5 , Floor 3 , No. 27 , West Rahimi Ave. , Mahan Blvd , Jahanshahr , Karaj</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3143754843</zip>
        <telephone>+98 26 3420 7972</telephone>
        <email>m.rezaei@abzums.ac.ir</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehdi Rezaee</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 5 , Floor 3 , No. 27 , West Rahimi Ave. , Mahan Blvd , Jahanshahr , Karaj</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3143754843</zip>
        <telephone>+98 26 3420 7972</telephone>
        <email>m.rezaei@abzums.ac.ir</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>written consent to participate in the study
age 18 to 65
candidate for instrumentation in posterior lumbar spine surgeries
ASA class I-II</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>patients withholding consent
infection
tumor
fracture in the area of surgery
speech impairments
mental retardation
preoperative neurological disorders
allergy to anesthetic drugs
patients with pacemaker
patients that have used ropivacaine, opioids, and NSAIDs one week before the surgery
failure in epidural catheter placement during the surgery
pregnancy
nausea and vomiting
severe hemodynamic changes such as bradycardia or blood pressure drop higher than 30% of average blood pressure
seizure
severe headache
progressive paresthesia of the lower limbs
decreased level of consciousness
changes in respiratory rate and order</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G89.18</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other acute postprocedural pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: dexamethasone (4 mg) + ropivacaine (0.2%, 25 ml) + epinephrine (1:200000) using Hemo-vac drain with epidural drug delivery capability. The epidural injection is repeated every 6 hours until 48 hours after the surgery.</i_keyword>
      <i_keyword>Control group: dexamethasone (4 mg) + ropivacaine (0.2%, 25 ml) + epinephrine (1:200000) using an epidural catheter. The epidural injection is repeated every 6 hours until 48 hours after the surgery.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The level of pain at the state of rest. Timepoint: Before the surgery, 8, 16, 24, 32, 40, 48 hours, and 4 months after the surgery. Method of measurement: Asking the patient, based on visual analogue scale (0=no pain, 1-3=mild pain, 4-7=moderate pain, and 8-10=severe pain).</prim_outcome>
      <prim_outcome>The level of pain at the state of motion. Timepoint: Before the surgery, 8, 16, 24, 32, 40, 48 hours, and 4 months after the surgery. Method of measurement: Asking the patient, based on visual analogue scale (0=no pain, 1-3=mild pain, 4-7=moderate pain, and 8-10=severe pain).</prim_outcome>
      <prim_outcome>The level of patient satisfaction with pain management. Timepoint: Upon discharge from the hospital, and 4 months after the surgery. Method of measurement: Asking the patient, based on a 0 to 10 score (0=not satisfied, 1-3=relative satisfaction, 4-7=high level of satisfaction, and 8-10=completely satisfied).</prim_outcome>
      <prim_outcome>The level of surgeon satisfaction (i.e., operating environment and the rate of bleeding). Timepoint: At the end of the surgery. Method of measurement: Asking the surgeon, based on a 0 to 10 score (0-2=not satisfied, 3-5=low level of satisfaction, 6-8=relative satisfaction, and 9-10=completely satisfied).</prim_outcome>
      <prim_outcome>The time of starting to move. Timepoint: The time of starting to move. Method of measurement: Asking the nurse.</prim_outcome>
      <prim_outcome>The time to first analgesic request. Timepoint: The time to first analgesic request. Method of measurement: Asking the nurse.</prim_outcome>
      <prim_outcome>The amount of postoperative bleeding. Timepoint: 48 hours after the surgery. Method of measurement: Evaluation of blood volume in Hemovac drain during the first 48 hours after surgery minus the volume of drug solution injected into the surgical wound.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Karaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-12-06</approval_date>
        <contact_name>Ethics committee of Alborz University of Medical Sciences</contact_name>
        <contact_address>Ethics Committee Office, Second Floor, Deputy of Research and Technology, Saffarian Alley, 45 Meters Golshahr Ave Karaj Alborz Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
